… For the 9 available studies, we extracted relevant data on immunogenicity to administered
vaccines as well as safety evaluations. For HPV immunogenicity the according to protocol (…

… dose is administered early in the academic year. Alternate administration schedules offer …
The purpose of this study was to test noninferiority of an alternate administration schedule of …

… of prophylactic human papillomavirus (HPV) vaccines has … vaccine administered has
been quadrivalent vaccine. In the US, there is both public and private financing for vaccines…

… A competitive serological assay shows naturally acquired immunity to human papillomavirus
… In 2014, the US Food and Drug Administration (FDA) approved a nonavalent vaccine …

… vaccination and increase vaccine administration. Early education about the human papillomavirus
… facts and safety information about the vaccine, may result in higher vaccination rates. …

… human papillomavirus vaccination and the appearance of post-vaccination symptoms. …
adverse symptoms after human papillomavirus vaccination, 163 patients with various post-…

… human papillomavirus vaccine was associated with same-day syncope and skin infections
in the 2 weeks after vaccination. … 9 to 26 years of age secondary to vaccination with HPV4. …

… Drug Administration (FDA) approved the first vaccine for prevention of cervical cancer based
on the molecular biology of the disease. Gardasil® (quadrivalent human papillomavirus […

… All three vaccines have been approved for administration in a 3-dose series at intervals
of 0, 1 or 2, and 6 months. In October 2016, after considering new clinical trial results (4), the …

… alone [58–61] and similar to those for the 2vHPV vaccine administered alone in other studies.
There was no increase in the frequency of solicited local or systemic adverse events with …